Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects
Public ClinicalTrials.gov record NCT00703703. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 3-way Cross-over, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess Pharmacologic Effects of a 7-day Exposure to Darifenacin 15 mg o.d. and Tolterodine ER 4 mg o.d. on Cardiovascular Parameters in Healthy Subjects 50 Years of Age and Older
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the pharmacologic effects of exposure to darifenacin and tolterodine on cardiovascular parameters in healthy subjects 50 years of age and older
Study identification
- NCT ID
- NCT00703703
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 117 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2008 (Type not available)
- Primary completion
- Oct 2008 (Actual)
- Completion
- Oct 2008 (Actual)
- Last update posted
- Aug 2, 2012
2008
United States locations
- U.S. sites
- 21
- U.S. states
- 14
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigative Site | Phoenix | Arizona | — | — |
| Investigative Site | Tempe | Arizona | — | — |
| Investigative Site | Little Rock | Arkansas | — | — |
| Investigative Site | San Diego | California | — | — |
| Investigative Site | Washington D.C. | District of Columbia | — | — |
| Investigative Site | Fort Myers | Florida | — | — |
| Investigative Site | Jacksonville | Florida | — | — |
| Investigative Site | Jupiter | Florida | — | — |
| Investigative Site | Miami | Florida | — | — |
| Investigative Site | Orlando | Florida | — | — |
| Investigative Site | Overland Park | Kansas | — | — |
| Investigative Site | Topeka | Kansas | — | — |
| Investigative Site | Riverdale | Maryland | — | — |
| Investigative Site | Wellesley Hills | Massachusetts | — | — |
| Investigative Site | Springfield | Missouri | — | — |
| Investigative Site | Hackensack | New Jersey | — | — |
| Investigative Site | Burlington | North Carolina | — | — |
| Investigative Site | Greensboro | North Carolina | — | — |
| Investigative Site | Oklahoma City | Oklahoma | — | — |
| Investigative Site | Knoxville | Tennessee | — | — |
| Investigative Site | Morgantown | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00703703, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 2, 2012 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00703703 live on ClinicalTrials.gov.